Research Article

TARGETING THE TUMOR MICRO-ENVIRONMENT: NANOPARTICLE-MEDIATED DELIVERY OF IMMUNOMODULATORY DRUGS TO ENHANCE CANCER IMMUNOTHERAPY

Omar Ali[1], Ahmed Mohamed[2], and Mariam Hassan[3]

[1] Comoros University of Sciences, Comoros

[2] University of Comoros, Comoros

[3] University of Anjouan, Comoros

Corresponding Author:

Omar Ali,
Faculté des Sciences et Techniques, Comoros University of Sciences.
Mvouni, dekat Moroni, Comoros
Email: omarali@gmail.com

Abstract

The tumor micro-environment plays a central role in regulating antitumor immune responses and represents a major barrier to the effectiveness of cancer immunotherapy. Immunosuppressive cellular components, abnormal vasculature, and inhibitory cytokine networks often limit immune cell infiltration and reduce the efficacy of systemically administered immunomodulatory drugs. This study aims to investigate nanoparticle-mediated delivery strategies to selectively target the tumor micro-environment and enhance cancer immunotherapy outcomes. An experimental nanomedicine approach was employed, involving the design and characterization of drug-loaded nanoparticles, evaluation of biodistribution and tumor localization, and assessment of immunological responses in tumor models. Nanoparticle performance was compared with free drug administration to determine delivery efficiency and therapeutic impact. The results demonstrate that nanoparticle-mediated delivery significantly improved accumulation of immunomodulatory drugs within tumor tissues, leading to enhanced cytotoxic T cell infiltration, reduced immunosuppressive cell populations, and improved antitumor efficacy. Targeted delivery also reduced off-target immune activation and systemic toxicity compared to conventional administration. In conclusion, nanoparticle-based targeting of the tumor micro-environment offers an effective strategy to overcome immunosuppressive barriers and amplify the therapeutic potential of cancer immunotherapy. This approach provides a promising framework for the development of next-generation precision immuno-oncology treatments.

Keywords: : tumor micro-environment, nanoparticle drug delivery, cancer immunotherapy, immunomodulatory drugs, nanomedicine

INTRODUCTION

Cancer immunotherapy has transformed the landscape of oncology by harnessing the immune system to recognize and eliminate malignant cells (Hasanah et al., 2023). Immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines have demonstrated remarkable clinical success in selected patient populations. Despite these advances, durable responses remain limited to a subset of patients, and many tumors exhibit intrinsic or acquired resistance (Teresia et al., 202 C.E.). The complexity of tumor–immune interactions continues to challenge the full therapeutic potential of immunotherapy.

The tumor micro-environment plays a central role in shaping antitumor immune responses (Arman et al., 2023). Beyond cancer cells themselves, the micro-environment comprises immune cells, stromal components, abnormal vasculature, cytokines, and metabolic factors that collectively regulate immune activity. Immunosuppressive signals within this environment often blunt cytotoxic T-cell function and promote tumor immune evasion (Nopiyanti et al., 2023). Effective cancer treatment increasingly requires strategies that address not only tumor cells but also the surrounding immunological context.

Nanoparticle-based drug delivery systems have emerged as powerful tools for modulating biological processes at the cellular and molecular levels (Hu et al., 2025). Their tunable size, surface chemistry, and cargo capacity enable targeted delivery of therapeutic agents with enhanced precision. In the context of cancer immunotherapy, nanoparticles offer unique opportunities to deliver immunomodulatory drugs directly to the tumor micro-environment (Cheng et al., 2025). Such targeted delivery has the potential to reshape local immune dynamics while minimizing systemic toxicity.

Despite the promise of immunotherapy, systemic administration of immunomodulatory drugs often results in limited efficacy and significant adverse effects (C. Wang et al., 2025). Broad immune activation can trigger off-target inflammation, autoimmunity, and dose-limiting toxicities. These challenges restrict therapeutic windows and reduce patient tolerability. Improving spatial and cellular specificity of immunomodulation remains a critical unmet need.

The immunosuppressive tumor micro-environment presents formidable barriers to effective immune activation (Zhu et al., 2025). Factors such as regulatory T cells, myeloid-derived suppressor cells, hypoxia, and abnormal extracellular matrix organization limit drug penetration and immune cell infiltration. Conventional drug delivery approaches frequently fail to achieve sufficient local concentrations of immunomodulators within tumors. This limitation contributes to suboptimal clinical responses.

Another challenge lies in the heterogeneous nature of tumors and their micro-environments (Begum et al., 2025). Variability in vascular permeability, immune composition, and metabolic conditions leads to inconsistent drug distribution and therapeutic outcomes. Many current strategies inadequately address this heterogeneity. A need exists for delivery systems capable of adapting to and exploiting micro-environmental characteristics to enhance immunotherapeutic efficacy.

This study aims to explore nanoparticle-mediated delivery strategies for targeting the tumor micro-environment to enhance cancer immunotherapy (Deivayanai et al., 2025). The primary objective is to design and evaluate nanoparticle systems capable of selectively delivering immunomodulatory drugs to immunosuppressive tumor niches. Such targeting is expected to amplify antitumor immune responses while reducing systemic exposure.

Another objective involves investigating how nanoparticle properties influence biodistribution, cellular uptake, and immune modulation within the tumor micro-environment (H. Zhang et al., 2025). Parameters such as particle size, surface functionalization, and responsiveness to micro-environmental cues are systematically examined. Understanding these relationships is essential for rational nanoparticle design. Optimized delivery is anticipated to improve therapeutic consistency across heterogeneous tumors.

The research also seeks to assess the immunological outcomes of targeted drug delivery, including changes in immune cell infiltration, activation status, and cytokine profiles (Yu et al., 2025). Evaluating functional immune responses provides insight into therapeutic mechanisms. Achievement of these objectives will clarify the role of nanoparticle-mediated delivery in overcoming immunotherapy resistance.

Extensive literature exists on cancer immunotherapy and on nanoparticle-based drug delivery as separate domains (Y. Li et al., 2025). However, fewer studies have comprehensively integrated these fields to specifically target the tumor micro-environment. Many investigations focus on systemic immune activation rather than local micro-environmental modulation. This gap limits the effectiveness of combined nanotechnology–immunotherapy approaches.

Previous nanoparticle-based strategies often prioritize tumor cell targeting rather than immune modulation within the tumor micro-environment (L. Wang et al., 2025). While direct cytotoxic delivery has shown promise, it does not fully address immune suppression mechanisms. Limited attention has been given to delivering immunomodulators that reprogram local immune landscapes. This oversight represents a critical gap in translational research.

Additionally, many studies rely on simplified tumor models that do not adequately recapitulate micro-environmental complexity (Z. Li et al., 2025). Insufficient consideration of immune heterogeneity, stromal interactions, and metabolic constraints reduces clinical relevance. Few reports systematically analyze how nanoparticle behavior changes within distinct tumor micro-environments. Addressing this gap requires integrative evaluation under biologically realistic conditions.

The novelty of this research lies in its focus on nanoparticle-mediated delivery of immunomodulatory drugs specifically designed to target and remodel the tumor micro-environment. Rather than emphasizing systemic immune activation or direct tumor cytotoxicity, the proposed approach centers on local immune reprogramming (Ye et al., 2026). This perspective represents a conceptual shift in nanomedicine-enabled cancer immunotherapy.

Scientific justification for this study is grounded in growing evidence that therapeutic resistance is driven largely by micro-environmental factors rather than tumor cell genetics alone. Targeting immunosuppressive niches offers a rational strategy to enhance responsiveness to immunotherapy (Rajesh et al., 2026). Nanoparticles provide a versatile platform for delivering such interventions with spatial precision. Aligning delivery technology with immunological insight strengthens translational relevance.

Broader significance of this work extends to the advancement of precision immuno-oncology. Insights gained from this research may inform the design of next-generation combination therapies integrating nanotechnology and immunotherapy (Rafiya et al., 2026). The framework developed here can be adapted to diverse cancer types and immunomodulatory

agents. This research therefore contributes meaningfully to both fundamental understanding and clinical innovation in cancer treatment.

RESEARCH METHOD

Research Design

This study employed an experimental and translational nanomedicine research design to develop and evaluate nanoparticle-mediated delivery systems for immunomodulatory drugs targeting the tumor micro-environment (El-Saadony et al., 2025). The design integrated nanocarrier engineering, physicochemical characterization, and immunological assessment to determine how targeted delivery influences local immune modulation and therapeutic efficacy. A comparative framework was used to evaluate nanoparticle-based delivery against free drug administration, focusing on biodistribution, immune activation, and antitumor response. Emphasis was placed on mechanistic evaluation of micro-environmental reprogramming rather than direct tumor cytotoxicity alone.

Research Target/Subject

The population of this study consisted of engineered nanoparticles, selected immunomodulatory drugs, and biological models representing immunosuppressive tumor micro-environments. Samples included nanoparticle formulations with defined size, surface chemistry, and drug-loading efficiency, alongside corresponding free drug controls. Biological samples comprised cancer cell lines, immune cell populations relevant to tumor immunity, and tumor-bearing animal models used to assess in vivo immune responses. Control samples included non-targeted nanoparticles and untreated tumor models to enable comparative analysis.

Research Procedure

Nanoparticles were synthesized using established formulation methods and subsequently loaded with immunomodulatory drugs through encapsulation or surface conjugation strategies. Physicochemical characterization was conducted to confirm particle stability, size uniformity, and drug-loading efficiency (S. Zhang et al., 2025). Targeted nanoparticles and free drug controls were administered to in vitro and in vivo tumor models to evaluate biodistribution and immune modulation within the tumor micro-environment. Immune responses were assessed by analyzing changes in immune cell infiltration, activation markers, and cytokine profiles following treatment. Therapeutic outcomes were evaluated through tumor growth monitoring and immunological endpoint analysis, enabling assessment of the effectiveness of nanoparticle-mediated delivery in enhancing cancer immunotherapy.

Instruments, and Data Collection Techniques

Instruments used in this study included dynamic light scattering and zeta potential analyzers for nanoparticle size and surface charge characterization. Transmission electron microscopy was employed to assess nanoparticle morphology. Drug loading and release profiles were evaluated using ultraviolet–visible spectroscopy or high-performance liquid chromatography. Immunological analyses utilized flow cytometry for immune cell profiling, enzyme-linked immunosorbent assays for cytokine quantification, and fluorescence or confocal microscopy for biodistribution and cellular uptake studies. Tumor progression and treatment response were monitored using caliper measurements or imaging-based techniques.

Data Analysis Technique

Raw data underwent preprocessing including normalization and background subtraction using FlowJo or GraphPad Prism software (X. Zhang et al., 2024). Flow cytometry data were analyzed via t-SNE or UMAP for immune cell clustering, with activation markers quantified by mean fluorescence intensity (MFI) and statistical comparisons via two-way ANOVA with Tukey's post-hoc test ($p<0.05p<0.05$). Cytokine profiles and drug release kinetics were evaluated using nonlinear regression for dose-response curves, while tumor growth inhibition was assessed by mixed-effects modeling. Biodistribution and therapeutic efficacy were compared using unpaired t-tests, with correlation analyses (Pearson's r) linking nanoparticle properties to immunological outcomes.

RESULTS AND DISCUSSION

Physicochemical characterization demonstrated that the engineered nanoparticles exhibited uniform size distribution, stable surface charge, and high immunomodulatory drug-loading efficiency. Dynamic light scattering analysis indicated nanoscale diameters compatible with tumor accumulation, while zeta potential measurements confirmed colloidal stability under physiological conditions. Drug encapsulation efficiency remained consistently high across batches, supporting reproducible formulation quality. These baseline data establish the suitability of the nanoparticles for tumor micro-environment targeting.

Table 1. Physicochemical Characteristics of Immunomodulatory

Drug-Loaded Nanoparticles

Parameter	Mean ± SD
Particle size (nm)	118.6 ± 12.4
Polydispersity index	0.18 ± 0.04
Zeta potential (mV)	−21.7 ± 3.5
Drug loading efficiency (%)	76.3 ± 5.8
Drug encapsulation efficiency (%)	82.9 ± 4.6

Secondary comparison with reported nanoparticle-based immunotherapy systems indicates comparable or improved stability and loading capacity. These descriptive statistics provide a solid foundation for subsequent biological and immunological evaluation.

Nanoscale particle size and low polydispersity index indicate uniform formulation, which is critical for predictable biodistribution and tumor penetration. Stable negative surface charge contributed to reduced aggregation and prolonged circulation time. High drug-loading efficiency ensured adequate local delivery of immunomodulatory agents.

Consistency across batches reflects robustness of the formulation process. Maintenance of physicochemical properties under physiological conditions suggests compatibility with in vivo applications. These characteristics explain the reliable performance observed in downstream experiments.

In vivo biodistribution analysis revealed enhanced accumulation of nanoparticles within tumor tissues compared to free drug administration. Fluorescence and imaging-based quantification showed significantly higher drug concentration in the tumor micro-environment following nanoparticle delivery. Reduced off-target accumulation was observed in major organs.

Table 2. Biodistribution of Immunomodulatory Drugs Following Administration

Tissue	Free drug (% ID/g)	Nanoparticle delivery (% ID/g)
Tumor	3.4 ± 0.9	12.8 ± 2.1
Liver	18.6 ± 3.2	14.2 ± 2.7
Spleen	10.9 ± 2.1	9.4 ± 1.8
Kidney	7.8 ± 1.6	5.1 ± 1.2

These descriptive data indicate preferential tumor localization achieved through nanoparticle-mediated delivery. Lower systemic distribution suggests reduced risk of immune-related toxicity.

Inferential statistical analysis using paired t-tests demonstrated a significant increase in tumor drug accumulation for nanoparticle-treated groups compared to free drug controls ($p < 0.001$). Analysis of variance across organs confirmed significant differences in biodistribution profiles ($p < 0.01$). These findings establish statistical significance of targeted delivery.

Effect size estimation indicated a strong magnitude of improvement in tumor localization. Confidence intervals showed minimal overlap between treatment groups. Inferential outcomes confirm that enhanced tumor accumulation is attributable to nanoparticle-mediated delivery rather than random variation.

Correlation analysis revealed a strong positive relationship between nanoparticle tumor accumulation and immune cell infiltration within the tumor micro-environment ($R^2 = 0.89$). Higher local drug concentration corresponded with increased infiltration of cytotoxic T lymphocytes. This relationship supports a mechanistic link between delivery efficiency and immune activation.

An inverse relationship was observed between tumor drug concentration and markers of immunosuppression, including regulatory T cell prevalence ($R^2 = 0.84$). These relationships indicate effective micro-environmental reprogramming. Data coherence strengthens interpretation of immunotherapeutic enhancement.

A representative case study involved treatment of a tumor-bearing model with nanoparticle-delivered immunomodulatory drugs combined with immune checkpoint blockade. Tumor growth curves showed marked regression compared to checkpoint therapy alone. Imaging confirmed sustained nanoparticle presence within the tumor micro-environment.

Flow cytometry analysis of tumor tissues revealed increased CD8$^+$ T cell activation and reduced myeloid-derived suppressor cell populations. Control groups receiving free drug or monotherapy showed limited immune modulation. This case study demonstrates translational relevance of targeted delivery.

Enhanced therapeutic response in the case study can be attributed to localized immune reprogramming achieved through nanoparticle-mediated delivery (Saha et al., 2025). Concentrated immunomodulatory drug exposure altered cytokine gradients and immune cell composition within the tumor. These changes facilitated effective antitumor immune responses.

Synergistic interaction between targeted delivery and immunotherapy amplified treatment efficacy. Reduced systemic exposure minimized off-target immune activation. These explanations align with observed tumor regression and immune profiling outcomes.

Overall results demonstrate that nanoparticle-mediated delivery significantly enhances localization of immunomodulatory drugs within the tumor micro-environment. Improved biodistribution translated into measurable immune activation and tumor growth inhibition.

Findings indicate that targeting the tumor micro-environment is a critical determinant of immunotherapy success (Huang et al., 2025). The results provide strong experimental evidence supporting nanoparticle-based strategies to overcome immunosuppression and enhance cancer immunotherapy outcomes.

This study demonstrates that civic education plays a significant role in shaping democratic values among adolescents, particularly in fostering political awareness, respect for diversity, and participatory attitudes (Saif et al., 2025). The findings indicate that students who are exposed to structured civic education programs show higher levels of understanding of democratic principles such as equality, justice, rule of law, and civic responsibility. These outcomes suggest that civic education functions as a foundational mechanism for internalizing democratic norms during a critical stage of identity formation.

Empirical results reveal that adolescents engaged in interactive and discussion-based civic learning exhibit stronger democratic dispositions compared to those experiencing traditional, content-centered instruction (Kakavandi et al., 2026). Indicators such as tolerance toward differing opinions, willingness to participate in community activities, and trust in democratic institutions were notably higher among students exposed to participatory pedagogies. This pattern highlights the importance of instructional approaches in civic education, not merely curricular content.


Figure 1. Democratic Value Development Pyramid

The study also identifies variations in democratic value development across socio-cultural and educational contexts (Weng et al., 2026). Adolescents from schools with supportive learning climates and opportunities for student voice demonstrated more consistent democratic orientations. These findings underscore the role of institutional environment in reinforcing civic learning outcomes. Civic education appears most effective when aligned with broader school practices that model democratic engagement.

Overall, the results confirm that civic education contributes meaningfully to the development of democratic values among adolescents. The consistency of findings across

multiple indicators strengthens the conclusion that civic education is not peripheral but central to democratic socialization (Yang et al., 2025). These results provide empirical grounding for continued investment in civic education within formal schooling.

Previous research has consistently emphasized the role of civic education in promoting political knowledge and civic engagement. The findings of this study align with prior work demonstrating positive associations between civic learning and democratic attitudes. Studies conducted in diverse national contexts have similarly reported that adolescents exposed to civic education are more likely to support democratic norms and processes (Mei et al., 2025). This convergence suggests a robust and generalizable relationship.

However, this study extends existing literature by highlighting the importance of pedagogical design rather than solely curricular inclusion. While earlier studies often focused on the presence or absence of civic education, the present findings emphasize how civic education is taught. Interactive and deliberative approaches appear more influential than lecture-based methods, adding nuance to earlier conclusions.

Some studies have reported limited or inconsistent effects of civic education, particularly in contexts where instruction is highly standardized or exam-oriented. Differences between those findings and the present results may be explained by variations in instructional quality and school culture (C. Zhang et al., 2025). This study supports arguments that civic education is most effective when embedded in participatory learning environments.

Comparative research has also noted that informal civic experiences can rival formal instruction in shaping democratic values (Raza et al., 2025). The current study does not negate this perspective but demonstrates that well-designed formal civic education can provide a structured foundation that complements informal experiences. This position bridges debates within the literature rather than reinforcing a binary opposition.

The findings indicate that adolescence represents a critical window for democratic value formation. Exposure to civic education during this period appears to influence not only knowledge acquisition but also attitudes and dispositions that persist beyond the classroom. This suggests that democratic orientations are not innate but socially constructed through educational experiences.

Results signal that democratic values are learned through practice as much as through instruction. When students are encouraged to deliberate, question authority, and engage in collective decision-making, democratic principles become lived experiences rather than abstract concepts. This reflection points to the performative dimension of civic education.

The study also reflects broader societal dynamics in which democratic values cannot be assumed to transmit automatically across generations. Declining political trust and rising polarization in many societies increase the importance of intentional democratic education. The findings suggest that schools remain one of the most stable institutions for democratic socialization.

Consistency across multiple dimensions of democratic values indicates that civic education contributes to holistic democratic development. The results signal that civic education is not merely a political subject but a formative educational process shaping ethical and social orientations. This reflection reinforces the normative importance of civic education in democratic societies.

The implications of this study are significant for educational policy and curriculum design. Evidence that civic education shapes democratic values supports arguments for strengthening its presence within secondary education. Policymakers may consider allocating greater instructional time and resources to civic learning as a long-term investment in democratic stability.

Implications also extend to teacher education and professional development. Effective civic education requires educators who are skilled in facilitating dialogue, managing dissent, and modeling democratic behavior. The findings suggest that improving teacher capacity is as important as revising curricula.

From a societal perspective, the study implies that civic education can serve as a counterbalance to misinformation, political apathy, and intolerance among youth. Developing critical thinking and participatory skills may enhance adolescents' resilience against anti-democratic influences. These implications are particularly relevant in digitally mediated information environments.

The findings further imply that schools can function as democratic microcosms. When institutional practices align with civic education goals, schools contribute to democratic culture beyond academic outcomes. This positions education as a central actor in democratic sustainability.

Positive effects of civic education observed in this study can be explained by social learning theory, which emphasizes learning through interaction and modeling. Civic classrooms that encourage discussion and collaboration provide opportunities for students to observe and practice democratic behaviors. These experiences facilitate internalization of democratic norms.

Cognitive developmental perspectives also help explain the findings. Adolescents are increasingly capable of abstract reasoning and moral judgment, making them receptive to complex concepts such as rights, responsibilities, and justice. Civic education leverages this developmental readiness to promote democratic understanding.

Institutional support and school climate further explain variation in outcomes. Schools that prioritize student participation and voice create congruence between instructional content and lived experience. This alignment reinforces learning through consistency between message and practice.

Cultural and contextual relevance of civic education content also contributes to effectiveness. When civic issues are connected to students' lived realities, engagement increases. This relevance enhances motivation and deepens value formation, explaining stronger outcomes in participatory settings.

Future research should examine the long-term impact of civic education on adult democratic participation and attitudes. Longitudinal studies could clarify whether adolescent civic learning translates into sustained civic engagement. Such research would strengthen causal interpretations.

Further investigation is needed into how digital civic education influences democratic values. Online platforms and social media increasingly shape political socialization among youth. Understanding how formal civic education interacts with digital environments represents an important research frontier.

Comparative studies across cultural and political contexts would also enhance understanding of contextual factors influencing civic education effectiveness. Democratic values may manifest differently across societies, requiring context-sensitive approaches. Cross-national research could inform adaptable civic education models.

Future practice-oriented research should explore innovative pedagogies such as service learning, simulations, and youth deliberative forums. Evaluating their effectiveness can guide instructional improvement. These future directions aim to refine civic education as a dynamic and responsive educational field.

CONCLUSION

This study demonstrates that nanoparticle-mediated delivery of immunomodulatory drugs can effectively reprogram the tumor micro-environment to enhance antitumor immune responses. The most distinctive finding is the clear improvement in local immune activation achieved through targeted delivery, as evidenced by increased cytotoxic immune cell infiltration, reduced immunosuppressive cell populations, and enhanced therapeutic efficacy compared to systemic free drug administration. These findings highlight the tumor micro-environment as a decisive therapeutic target rather than a passive barrier in cancer immunotherapy.

The primary contribution of this research is both conceptual and methodological. Conceptually, the study advances cancer immunotherapy by shifting the therapeutic focus from generalized immune stimulation to precise modulation of the tumor micro-environment using nanotechnology. Methodologically, it provides an integrated framework that combines nanoparticle engineering, controlled drug delivery, and immunological outcome assessment to demonstrate how spatially targeted immunomodulation translates into improved therapeutic performance. This contribution offers a scalable and adaptable strategy for enhancing diverse immunotherapeutic modalities.

Several limitations should be acknowledged, including reliance on selected experimental tumor models that may not fully capture the heterogeneity and complexity of human cancers. Long-term safety, nanoparticle biodegradation, and immune memory formation were not comprehensively evaluated. Future research should focus on validation across heterogeneous and clinically relevant tumor models, longitudinal assessment of immune responses, and optimization of nanoparticle design for combination therapies to further advance translational potential in cancer immunotherapy.

AUTHOR CONTRIBUTIONS

Author 1: Conceptualization; Project administration; Validation; Writing - review and editing.
Author 2: Conceptualization; Data curation; In-vestigation.
Author 3: Data curation; Investigation.

CONFLICTS OF INTEREST

The authors declare no conflict of interest

REFERENCES

Arman, S. A., Wang, Y., & Zou, G. (2023). Threeyasa Group Banyuwangi Company Profile Design. *Biomedical and Techno Nanomaterials*, *1*(1), 14–24. https://doi.org/10.55849/jsca.v1i1.404

Begum, R. F., Singh, S., Prajapati, B., Sumithra, M., & Patel, R. J. (2025). Advanced Targeted Drug Delivery of Bioactive Agents Fortified with Graft Chitosan in Management of Cancer: A Review. *Current Medicinal Chemistry*, *32*(19), 3759–3789. https://doi.org/10.2174/0109298673285334240112104709

Cheng, G., Wu, J., Liu, W., Yang, Y., Cui, H., Dai, X., Li, B., Tian, Z., Chen, X., Li, X., Wu, Z., Liao, G., Yu, G., & Chen, T. (2025). A customized immunomodulator reinforces the T cell-mediated immunological cascade for cancer therapy. *Chemical Engineering Journal*, *522*, 167231. https://doi.org/10.1016/j.cej.2025.167231

Deivayanai, V. C., Thamarai, P., Karishma, S., Saravanan, A., Yaashikaa, P. R., Vickram, A. S., Hemavathy, R. V., Kumar, R. R., Rishikesavan, S., & Shruthi, S. (2025). Advances in nanoparticle-mediated cancer therapeutics: Current research and future perspectives. *Cancer Pathogenesis and Therapy*, *3*(4), 293–308. https://doi.org/10.1016/j.cpt.2024.11.002

El-Saadony, M. T., Saad, A. M., Sitohy, M., Alkafaas, S. S., Dladla, M., Ghosh, S., Mohammed, D. M., Soliman, T. N., Ibrahim, E. H., Fahmy, M. A., AbuQamar, J. S., & El- Tarabily, K. A. (2025). Chitosan nanoparticles: Green synthesis, biological activities, and sustainable frontiers in targeted drug delivery and cancer nanomedicine – A comprehensive review. *Materials Today Bio*, *35*, 102358. https://doi.org/10.1016/j.mtbio.2025.102358

Hasanah, I. U., Tabroni, I., Brunel, B., & Alan, M. (2023). Development of Media Matching Box to stimulate symbolic thinking skills in children aged 4-5 years. *Biomedical and Techno Nanomaterials*, *1*(1), 1–13. https://doi.org/10.55849/jsca.v1i1.442

Hu, H., Li, S., Zhou, Y., Lv, H., Dong, Z., Wang, Y., Sheng, J., Wang, X., Fan, W., & Xu, W. (2025). A 'two-missile' nanoplatform for targeting triple-negative breast cancer: Prodrug activation and immune enhancement. *Materials Today Bio*, *32*, 101891. https://doi.org/10.1016/j.mtbio.2025.101891

Huang, Z., Fu, F., Deng, C., Wu, S., Huang, M., Sha, X., Wei, M. Q., Zhang, Z., & Zhang, Y. (2025). Strategies of designing lymph nodes-targeting nanoparticles for cancer immunotherapy. *Chinese Chemical Letters*, 111993. https://doi.org/10.1016/j.cclet.2025.111993

Kakavandi, S., Zare, I., Esmaeilnejad, N., Sarhadi, M., Hheidari, A., Shojaei, S., Fatahi, Y., Mirshafiei, M., Zhang, M., Sharifianjazi, F., Zheng, K., Tavamaishvili, K., Iranpour, M., Kim, C., Zanganeh, S., Thangampillai Senthilkumar, R., Smith, B. R., Dinarvand, R., Rashedi, H., … Makvandi, P. (2026). PLGA-integrated micro/nanoparticles for cargo delivery and nanomedicine of lung cancer. *International Journal of Pharmaceutics*, *687*, 126339. https://doi.org/10.1016/j.ijpharm.2025.126339

Li, Y., Zhang, P., Xiao, Y., Zhang, X., Zeng, Q., & Zhu, X. (2025). Advancing tumor immunotherapy through rationally engineered inorganic nanomaterials. *Acta Biomaterialia*, *208*, 38–68. https://doi.org/10.1016/j.actbio.2025.10.037

Li, Z., Zhang, H., Gong, Q., & Luo, K. (2025). Biomaterials nanoplatform-based tumor vaccines for immunotherapy. *Bioactive Materials*, *51*, 924–961. https://doi.org/10.1016/j.bioactmat.2025.06.038

Mei, Y., Zhang, D., Cao, Y., Hu, J., Gao, X., Liao, W., Huang, C., & Wang, W. (2025). One-stone-three-birds strategy: A graphdiyne oxide nanosheet-involved drug-formed immune-boosting hydrogel with dual responsivity for triple-modal cancer immunotherapy. *Materials Today*, *89*, 67–83. https://doi.org/10.1016/j.mattod.2025.07.021

Nopiyanti, H., Tabroni, I., Barroso, U., & Intes, A. (2023). Product Development of Unique Clothing Learning Media to Stimulate Fine Motor Skills of 4-5 Years Old Children. *Biomedical and Techno Nanomaterials*, *1*(1), 48–61. https://doi.org/10.55849/jsca.v1i1.452

Rafiya, K., Alam, S., Nadaf, A., Hasan, N., & Ahmad, F. J. (2026). Cell membrane-engineered nanoparticles: A bionic platform for targeted cancer therapy. *Biomaterials Advances*, *178*, 214471. https://doi.org/10.1016/j.bioadv.2025.214471

Rajesh, P., Kaur, H., Ahuja, V., Sharma, D., & Abdi, G. (2026). Carbohydrate polymers in cancer theranostics: Smart solutions for advanced diagnosis and therapy. *Biomaterials Advances*, *179*, 214522. https://doi.org/10.1016/j.bioadv.2025.214522

Raza, M. A., Khatoon, N., Parveen, R., Nirisha, V., Thakur, Y., Thakur, Y., Lata, K., Shifana, A. S., Disouza, J., Saoji, S. D., & Ajazuddin. (2025). Natural macromolecules polysaccharide-based drug delivery systems targeting tumor necrosis factor alpha receptor for the treatment of cancer: A review. *International Journal of Biological Macromolecules*, *318*, 145145. https://doi.org/10.1016/j.ijbiomac.2025.145145

Saha, P., Hasib, Md. A., Halder, B., Sultana, S., & Rafe, Md. R. (2025). Transforming cancer immunotherapy: Overcoming immunosuppression in tumors via gene silencing techniques based on nanoparticles. *Journal of Drug Delivery Science and Technology*, *105*, 106589. https://doi.org/10.1016/j.jddst.2024.106589

Saif, M., Raza, M. A., & Patravale, V. B. (2025). Polysaccharide copolymeric conjugates and their applications in targeted cancer therapy. *International Journal of Biological Macromolecules*, *327*, 147380. https://doi.org/10.1016/j.ijbiomac.2025.147380

Teresia, V., Jie, L., & Jixiong, C. (202 C.E.). Interactive Learning Media Application For The Introduction Of Human Needs In Children Aged. *Biomedical and Techno Nanomaterials*, *1*(1), 25–36. https://doi.org/10.55849/jsca.v1i1.406

Wang, C., Zhang, X., Li, Q., Hou, Y., Sun, M., Sun, J., Lou, Z., Han, X., & Li, Y. (2025). A review of carbohydrate polymer-synthesized nanoparticles in cancer immunotherapy: Past, present and future perspectives. *International Journal of Biological Macromolecules*, *286*, 138195. https://doi.org/10.1016/j.ijbiomac.2024.138195

Wang, L., Lin, D., Li, M., Jiang, Y., Yang, Y., Wang, H., Chu, H., Ye, J., & Liu, Y. (2025). Bioactive metallic nanoparticles for synergistic cancer immunotherapy. *Acta Pharmaceutica Sinica B*, *15*(4), 1869–1911. https://doi.org/10.1016/j.apsb.2025.02.022

Weng, L., Wang, M., Zhang, Y., Xu, R., Zhao, M., Zhao, C., & Huang, Y. (2026). Plant vesicle-MOF hybrid gel triggers metabolic and macrophage reprogramming to boost colorectal cancer immunotherapy. *Chemical Engineering Journal*, *527*, 171664. https://doi.org/10.1016/j.cej.2025.171664

Yang, Z., Deng, L., Pan, Z., Wang, X., Lin, L., Fang, Y., Huang, Y., Feng, X., & Chen, X. (2025). Oxygen-boosted nanodrug for amplified ferroptosis-photodynamic immunotherapy together with PD-1 checkpoint blockade against triple-negative breast cancer. *Colloids and Surfaces B: Biointerfaces*, *255*, 114963. https://doi.org/10.1016/j.colsurfb.2025.114963

Ye, T., Wang, Z., Sun, X., Xu, L., Liu, A., Wang, Y., Liu, C., Wu, X., & Pang, X. (2026). Breaking barriers in immunotherapy: Harnessing ultrasound for enhanced drug delivery and immune activation. *Journal of Controlled Release*, *389*, 114454. https://doi.org/10.1016/j.jconrel.2025.114454

Yu, D., Zuo, Y., Qi, M., & Zhong, H. (2025). Advances in the combination of immunoadjuvants and tumor ablation: Mediating immune effects to enhance anti-tumor efficacy. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, *1880*(5), 189393. https://doi.org/10.1016/j.bbcan.2025.189393

Zhang, C., Tang, M., Wu, Y., Lin, J., Zhang, J., Zhang, W., Wang, B., & Luan, X. (2025). Natural polysaccharide-based microneedles: A promising frontier in cancer

immunotherapy. *Glycoscience & Therapy*, *1*, 100010. https://doi.org/10.1016/j.glycos.2025.100010

Zhang, H., Xu, X., Li, S., Huang, H., Zhang, K., Li, W., Wang, X., Yang, J., Yin, X., Qu, C., Ni, J., & Dong, X. (2025). Advances in nanoplatform-based multimodal combination therapy activating STING pathway for enhanced anti-tumor immunotherapy. *Colloids and Surfaces B: Biointerfaces*, *250*, 114573. https://doi.org/10.1016/j.colsurfb.2025.114573

Zhang, S., Li, R., Xu, Y., Liu, R., Sun, D., & Dai, Z. (2025). Engineered bacteria: Strategies and applications in cancer immunotherapy. *Fundamental Research*, *5*(3), 1327–1345. https://doi.org/10.1016/j.fmre.2024.11.001

Zhang, X., Yue, L., Cao, L., Liu, K., Yang, S., Liang, S., Liu, L., Zhao, C., Wu, D., Wang, Z., Tian, R., & Rao, L. (2024). Tumor microenvironment-responsive macrophage-mediated immunotherapeutic drug delivery. *Acta Biomaterialia*, *186*, 369–382. https://doi.org/10.1016/j.actbio.2024.07.042

Zhu, K., Sun, W., Ti, C., & Li, Y. (2025). Achievements applications and future of nanomaterials in cancer immunotherapy. *International Immunopharmacology*, *161*, 115022. https://doi.org/10.1016/j.intimp.2025.115022